On the way to a more physiological hormonal contraception.
The newest form of Biogest, an oral contraceptive developed and modified by Czechoslovak researchers, involves a regimen with characteristics of both combination and sequential therapies of the traditional types. .08 mg of mestranol and .25 mg of either Chlor- or Bromsuperlutin are taken during the first phase of the cycle, while the second phase requires a pill with the same amount of the estrogen but with 1 mg of either Chlor- or Bromsuperlutin. Since in a normal menstrual cycle, some progesterone is always present during the first phase, the therapy is considered to be more physiological in nature than past sequential therapies. When the therapy was administered to 284 women during a total of 1236 cycles, no unwanted pregnancy occurred. Side effects were few and low in intensity. A high regularity of cycles occurred. A present multicenter study is in progress at 20 clinical and institutional investigation centers to establish the pregnancy rate unequivocally; about 10,000 cycles are involved.